|
- The NHS Research and Development
Priorities in Cancer Advisory Group of the Central Research and
Development Committee (CRDC) was established in November 1993 to
identify and rank priorities for research and development relating to
cancer that are of importance to the NHS. The Advisory Group was
chaired by Professor Peter Selby, St James's University Hospital,
Leeds, and comprised 15 members with expertise in the organisation,
management and delivery of cancer services and in research into
cancer. This was the fifth exercise to identify research and
development (R&D) needs in an area of top priority within the NHS
R&D Programme.
- The Advisory Group recommends
25 R&D priority areas in relation to cancer. Criteria for
selection included the burdens and costs to patients, carers and the
NHS, possible benefits from research and research feasibility. The 25
priorities are listed in Table 1 and at Annex
9 with an accompanying
set of justifications. The priorities are presented as either very
high priorities or high priorities. They are ordered to reflect the
natural chronological progression of the illness of cancer.
- The Advisory Group makes
additional recommendations. They concern: the need to maintain a
comprehensive infrastructure for clinical trials through
the collaboration of all interested parties, including the NHS; the
need for a thorough examination, including overviews, of existing
randomised trials for cancer management; the need to recognise
the importance of cancer registries as a valuable research tool
and also for planning and monitoring cancer services; and studies on
the economic costs of cancer to the NHS. In addition, in order
to help with the commissioning of the research, the Group advises a
search be made for present or imminent research activity in the areas
of the 25 priorities.
- The report details the membership
of the Advisory Group, its remit and the history of how the list of
priorities was created.
Next
Page (Introduction)
CRDC
Report: Contents Page
|